A Phase II Study of Durvalumab in Patients With Mismatch Repair Deficient or POLE Mutated Metastatic Colorectal Cancer

Trial Profile

A Phase II Study of Durvalumab in Patients With Mismatch Repair Deficient or POLE Mutated Metastatic Colorectal Cancer

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2018

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Adenocarcinoma; Colon cancer; Rectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Feb 2018 Planned initiation date changed from 1 Mar 2018 to 5 Mar 2018.
    • 19 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top